True Diagnostics

True Diagnostics is a private, commercial-stage company operating in the high-growth point-of-care diagnostics market. Its core asset is the TrueDX cassette technology, a patented lateral flow platform featuring integrated multi-point calibration for quantitative analysis, bridging the gap between simple qualitative tests and complex lab assays. The company employs a hybrid business model, both developing its own tests and offering comprehensive contract development and manufacturing (CDMO) services from its FDA-licensed, ISO 13485-certified facility. With products already commercially available in major retail pharmacies, True Diagnostics is positioned at the intersection of consumer health and professional diagnostics.

TrueDX Cassette Technology: A proprietary lateral flow assay platform with patented internal multi-point calibration enabling quantitative, lab-quality analysis at the point of care. Supports colorimetric, fluorescent, and electrochemical detection for high-sensitivity, multiplexed tests.

True Diagnostics competes in the crowded rapid diagnostics market against giants like Abbott (BinaxNOW, i-STAT), QuidelOrtho, and Roche, as well as numerous startups. Its key differentiation is the claim of quantitative results via integrated calibration on a lateral flow platform. Competition also comes from CDMO providers in the diagnostics space who offer development and manufacturing services.